Liquid Drug Products

Coriolis Pharma develops and manufactures liquid drug products—including formulation work requiring solvents, co-solvents and excipients selection—and formulation lifecycle management. Additionally, we can manufacture a developed formulation for preformulation, toxicology and proof of concept, as well as lead lot stability studies.

Automated Filling Equipment for Liquid Drug Products

We utilize modern automated filling equipment: the Flexicon FPC50 system, including LAF by Franz Ziel. This state-of-the-art solution is capable of processing all common vial formats and addressing non-GMP batch size needs ranging from a few dozen vials to several thousand.

Coriolis also provides filling solutions for non-vial container formats, including:

Prefilled syringes
Cartridges
Safe-lock tubes
Cryotubes
Custom container formats

We offer flexible semiautomated or manual filling solutions for small batches and products up to biosafety level 2.

Liquid drug product batch size capabilities
2 ml vials (2R)	15,000 vials/day
6 ml vials (6R)	8,000 vials/day
10 ml vials (10R)	8,000 vials/day
20 ml vials (20R)	4,000 vials/day
50 ml vials (50R)	2,000 vials/day

We’ve worked with more than 930 compounds, and that number is growing by the day.

Liquid Drug Product Manufacturing for Ranging Modalities

Coriolis Pharma’s deep expertise across many biologic modalities, combined with input from world-leading external advisors, offers the knowledge and experience needed to solve even the most complex formulation and drug development challenges. We’ve worked with more than 930 compounds, including drug substances like live virus vaccines, viral vectors or cell therapies that require biosafety level 2.

Antibody or Related Product

Peptide

Therapeutic Protein

Gene & Cell Therapy

Viral Vector

Nucleic Acid

Vaccine

Nanoparticulate Delivery Systems

Your Phase

Our expert team has the expertise and experience to guide your liquid drug product from preclinical and early-phase development to the market.

Preclinical

Early Phase

Late Phase & Commercialization

Commercial Services

Coriolis Effect

See how our expertise and comprehensive services accelerate biologics development from preclinical to the market.